Adebrelimab
- Generic Name
- Adebrelimab
- Drug Type
- Biotech
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
Socazolimab Shows Promise in Treating Extensive-Stage Small Cell Lung Cancer
A phase 3 clinical trial demonstrates that Socazolimab, combined with etoposide and carboplatin (EC), significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC) compared to placebo plus EC, offering a new hope in the treatment of this aggressive cancer subtype.
Toripalimab Plus Chemotherapy Improves Survival in Lung Cancer
• A phase III trial showed that adding toripalimab to chemotherapy significantly improved progression-free survival in extensive-stage small cell lung cancer.
• The combination of toripalimab and chemotherapy also led to a statistically significant improvement in overall survival compared to chemotherapy alone.
• Genomic analysis identified potential biomarkers, such as mutations in the FA-PI3K-Akt and IL-7 signaling pathways, associated with improved outcomes with toripalimab.
• The addition of toripalimab to chemotherapy showed an acceptable safety profile, supporting its use as a new treatment option.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath